Inadequate treatment response to des‐enkephalin‐gamma‐endorphin compared with thioridazine and placebo in schizophrenia

Acta Psychiatrica Scandinavica

Volumn 86, Issue 2, 1992, Pages 97-103

  Montgomery, S A ^a   Green, M ^a   Rimon, R ^b   Heikkila L ^c   Forsstrom R ^c   Hirsch, S R ^d   Hallstrom, C ^d   Hippius, H ^e   Naber, R ^e   Khan, M C ^f   Sitsen, J M A ^g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Uusikaupunki Hospital ^*  (Finland)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Hartlepool Hospital ^*  (United Kingdom)

^g NV ORGANON   (Netherlands)

Author keywords

endorphin; schizophrenia; thioridazine

Indexed keywords

GAMMA ENDORPHIN[DEENKEPHALIN]; GAMMA ENDORPHIN[DETYROSINE]; PLACEBO; THIORIDAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMPARISON; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA;

ADULT; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; ENDORPHINS; FEMALE; HUMAN; MALE; MIDDLE AGE; MODELS, THEORETICAL; PLACEBOS; SCHIZOPHRENIA; THIORIDAZINE;

EID: 0026667881     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1992.tb03235.x     Document Type: Article

References (37)

1. Involvement of non‐opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post mortem studies
2. Behavioural and electrophysiological effect of peptides related to lipotropin (beta‐LPH)
3. Similarity between behavioural effects of des‐tyrosine‐gamma‐endorphin and haloperidol and of alpha‐endorphin and of amphetamine
4. Immunohistochemical evidence for a dynorphin immuoreactive striato‐nigral pathway
5. Dynorphin and substance P pathways in the central nervous system. Neurochemical and functional studies
6. The C fragment of beta‐lipotropin: and endogenous neuroleptic or antipsychotogen
7. Endorphins: profound behavioural effects in rats suggest new etiological factors in mental illness
8. Naloxoneinduced reversal of schizophrenic hallucinations
9. Betaendorphins: intravenous infusion causes behavioral change in psychiatric patients
10. Behavioural and biological effects of acute beta‐endorphin injection in schizophrenic and depressed patients
11. Beta‐endorphin and schizophrenia
12. New treatments for schizophrenia an update.
13. Selective conversion of betaendorphin into peptides related to χ‐and gamma‐endorphin
14. Psychopathology as a neuropeptide dysfunction.
15. Presence of alpha‐endorphin, gamma‐endorphin and their des‐tyrosine fragments in rat pituitary and brain tissue
16. Non‐opiate beta‐endorphin fragments and dopamine IV gamma‐type endorphins may control dopaminergic systems in the nucleus accumbens
17. Increased levels of endorphins in chronic psychosis
18. Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states
19. High‐dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia
20. CSF betaendorphin in schizophrenia
21. Endogenous opiate activity and beta‐endorphin immunore‐activity in CSF of psychiatric patients and normal volunteers.
22. Specific regional differences in in vitro beta‐endorphin metabolism in schizophrenics.
23. Gamma‐(endorphin and schizophrenia: amino acid composition of gamma‐endorphin and nucleotide sequence of gamma‐endorphin cDNA from pituitary glands of schizophrenic patients
24. Distribution of beta‐endorphin in normal and schizophrenic human brains
25. 1)‐gamma‐endorphin.
26. (Des‐tyrosine) gamma‐endorphin in schizophrenia: clinical, biochemical and hormonal aspects
27. Des‐tyrosyl‐gamma‐endorphin in schizophrenia: a double‐blind trial in 13 patients
28. Clinical trials with des‐tyr‐gamma‐endorphin (GK‐78).
29. Des‐tyrosine‐gamma‐endorphin administration in chronic schizophrenics
30. Antipsychotic properties of des‐enkephalin‐gamma‐endorphin in treatment of schizophrenic patients
31. A comparative study on the antipsychotic properties of desenkephalin‐gamma‐endorphins and ceruletide in schizophrenic patients
32. Des‐enkephalin‐ gamma‐endorphin in the treatment of schizophrenia
33. Multicenter double‐blind comparison between desenkephalin‐gamma‐endorphin (DE‐gamma‐E Org. 5878) and haloperidol concerning the efficacy and safety in the treatment of schizophrenia
34. Development of a schizophrenic scale sensitive to change
35. The comprehensive psychopathological rating scale
36. The use of cholecystokinin in schizophrenia
37. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients